Just a moment, the page is loading...

*EISAI-E7080-G000-304




A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma
lenvatinib
E7080-G000-304
NCT01761266
EU CTR 2012-002992-33
Hepatocellular Carcinoma (HCC)
Phase 3
 
No restrictions.
November 2018